PBS updates

Keytruda (Pembrolizumab)

pembrolizumab 100 mg/4 mL injection, 4 mL vial · INJECTION · PBS code 10475H

STREAMLINED

What it costs

AU$3632.56 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2017-07-01.
  • • Repeats: 5.
  • • PBS program: IN.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Unresectable Stage III or Stage IV malignant melanoma


Initial treatment - 3 weekly treatment regimen


Patient must not have received prior treatment with nivolumab plus relatlimab, ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma; AND

Patient must not have experienced disease progression whilst on either: (i) PD-1 inhibitor treatment, (ii) CTLA-4 inhibitor treatment, if previously treated for resected or resectable melanoma; or

Patient must not have experienced disease recurrence within 6 months of completing either: (i) PD-1 inhibitor treatment, (ii) CTLA-4 inhibitor treatment, if previously treated for resected or resectable melanoma; AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

The treatment must not exceed a total of 6 doses under this restriction.

Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd ABN 14 000 173 508

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.